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Abstract: BACKGROUND: Mastocytosis is a clonal disorder characterized by the accumulation of abnormal mast cells in the skin and/or in extra-
cutaneous organs. OBJECTIVES: To present all cases of mastocytosis seen in the Porto Hospital Center and evaluate the performance of World
Health Organization diagnostic criteria for systemic disease. METHODS: The cases of twenty-four adult patients with mastocytosis were
reviewed. Their clinical and laboratorial characteristics were assessed, and the properties of the criteria used to diagnose systemic mastocyto-
sis were evaluated. RESULTS: The age of disease onset ranged from 2 to 75 years. Twenty-three patients had cutaneous involvement and 75%
were referred by dermatologists. Urticaria pigmentosa was the most common manifestation of the disease. One patient with severe systemic
mast cell mediator-related symptoms showed the activating V560G KIT mutation. The bone marrow was examined in 79% of patients, and
mast cell immunophenotyping was performed in 67% of the participants. Systemic disease was detected in 84% of cases, and 81% of the sam-
ple had elevated serum tryptase levels. All the diagnostic criteria for systemic mastocytosis had high specificity and positive predictive value.
Bone marrow biopsy had the lowest sensitivity, negative predictive value and efficiency, while the highest such values were observed for mast
cell immunophenotyping. Patients were treated with regimens including antihistamines, sodium cromoglycate, alpha-interferon, hydroxyurea
and phototherapy. CONCLUSIONS: Cutaneous involvement is often seen in adult mastocytosis patients, with most individuals presenting with
indolent systemic disease. Although serum tryptase levels are a good indicator of mast cell burden, bone marrow biopsy should also be per-
formed in patients with normal serum tryptase, with flow cytometry being the most adequate method to diagnose systemic disease.
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INTRODUCTION
The term ‘mastocytosis’ designates a heteroge-
neous group of disorders characterized by the abnor-
mal clonal proliferation and accumulation of mast
cells (MC) in one or multiple organs and/or tissues
including the skin, bone marrow (BM), liver, spleen,
and lymph nodes.1
Its clinical presentation is variable, ranging
from skin-limited disease, especially in pediatric cases
which spontaneously resolve over time, to a more
aggressive condition involving extracutaneous sites
and associated with multiple organ dysfunction/fail-
ure and shortened survival.2,3,4 Diseases involving the
pathologic proliferation of MC are classified based on
their clinical presentation, pathologic findings, and
prognosis. The 2008 World Health Organization
(WHO) classification divided tumors into the follow-
ing categories (Chart 1): 1) Cutaneous mastocytosis
(limited to the skin); 2) Extracutaneous mastocytosis
(unifocal MC tumor with low-grade cellular atypia
and non-destructive features); 3) Mast cell sarcoma
(unifocal mast cell tumor with destructive features
and poorly differentiated MC); 4) Systemic mastocyto-
sis (SM), which almost invariably involves the BM,
frequently presents with skin lesions and is the most
commonly diagnosed MC disorder in adults.5,6,7 The
diagnostic criteria for SM were also established by the
same 2008 WHO document (Chart 2).5,8 Patients are
diagnosed with SM upon fulfilling one major and one
minor or three minor criteria.
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SM has been associated with somatic mutations
in the v-kit Hardy-Zuckerman 4 feline sarcoma viral
oncogene homolog (KIT), which codes for a trans-
membrane receptor with kinase activity (KIT receptor,
CD117) whose ligand is the stem cell factor
(SCF).9 KIT mutations that induce ligand independent
phosphorylation of the SCF receptor and consequent-
ly lead to constitutive activation seem to play a criti-
cal role in the pathogenesis of SM by inducing
autonomous MC growth. As such, these mutations
may be potential diagnostic markers and therapeutic
targets. Two activating point mutations leading to the
amino acid substitutions Asp-816(r)Val and Val-
560(r)Gly in the proto-oncogene C-KIT have been
reported in the human mast cell leukemia cell line
HMC-1,  and also in adult-onset mastocytosis,
although with very different frequencies.10 The D816V
mutation has also been found to be common in adult
mastocytosis patients, and its frequency in adult indi-
viduals with SM is estimated to be higher than 80%,
although its presence does not necessarily imply asso-
ciated hematologic disease and is not a reliable prog-
nostic indicator, as was initially suggested.11,12,13 In con-
trast, the V560G mutation has been reported in only a
small number of patients.14,15 Patients with CM have
the best prognosis, followed by those with indolent
systemic mastocytosis (ISM). Patients with SM associ-
ated with clonal hematologic non-mast cell lineage
disease (SM-AHNMD), aggressive systemic mastocy-
tosis (ASM), or mast cell leukemia (MCL) experience
a more rapid and complex clinical course.
The purpose of the present study was to review
all cases of mastocytosis seen in a university hospital,
and to evaluate the use of WHO diagnostic criteria for
systemic disease.
Variants and subvariants
Cutaneous mastocytosis (CM)
Urticaria pigmentosa (UP)
Maculopapular CM (MPCM)
Diffuse CM (DCM)
Mastocytoma of skin
Indolents systemic mastocytosis (ISM)
Smoldering SM
Isolated bone marrow mastocytosis
Systemic mastocytosis with an associated clonal
hematologic non-mast cell lineage disease (SM-
AHMD)
Acute myeloblastic leukemia (SM-AML)
Myelodysplastic syndrome (SM-MDS)
Myeloproliferative disorder(SM-MPD)
Chronic myelomonocytic leukemia (SM-CMML)
Non-hodgkin lymphoma (SM-NHL)
Aggressive systemic mastocytosis (ASM)
Mast cell leukemia (MCL)
Aleukemic MCL
Mast cell sarcoma
Extracutaneous mastocytoma
CHART 1: Mastocytosis variants and subvariants according
to the 2008 World Health Organization classification5
Major criteria:
Multifocal dense infiltrates of mast cell (MC) detected in bone marrow (BM) and/or other extracutaneous
organs.
Minor criteria:
In MC infiltrates detected in BM or other extracutaneous organs, >25% of MC are spindle shaped or in BM
smears, atypical MC comprise >25 of all MC.
Detectation of codon 816 C-Kit point mutation in BM, blood or other extracutaneous organs.
BM, bood or other extracutaneous organs MC are CD2+ and/or CD25+.
Serum total tryptase persistently >20µg/L
CHART 2: World Health Organization criteria for the diagnosis of systemic mastocytosis 5*
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Footnotes: * The diagnosis is made when individuals meet 1 major and 1 minor or 3 minor criteria
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MATERIAL AND METHODS
Between January 2003 and March 2011, 24 adult
patients with mastocytosis were assessed at the multi-
disciplinary center for cutaneous lymphoma in the
Porto Hospital Center. Patient charts were retrospec-
tively reviewed for information on their disease, treat-
ment and outcome.
The initial evaluation included a physical
examination, full blood count, biochemical survey,
and the assessment of serum immunoglobulin, vita-
min B12, folate, ferritin and total tryptase serum levels
(range: 2-13 µg/L). Suspected cutaneous lesions were
biopsied, and all patients underwent BM biopsy and
aspirate in order to confirm the diagnosis and detect
systemic disease. Biopsy specimens were routinely
processed and stained with hematoxylin and eosin.
When necessary, CD117 expression was assessed by
immunohistochemical staining. BM aspirate smears
were stained with Leishman’s and toluidine blue
stains. Additionally, BM MC were immunopheno-
typed by flow cytometry. MC were quantified and
phenotyped by four-color staining using fluo-
rochrome-conjugated monoclonal antibodies directed
against CD2, CD25, CD45 and CD117. All patients
with SM underwent bone mineral density testing and
abdominal ultrasound at diagnosis.
The diagnostic properties of each WHO criteri-
on were evaluated by calculating sensitivity, specifici-
ty, predictive values and efficiency, using the WHO
requirements for the diagnosis of SM (1 major and 1
minor or 3 minor criterion) as the gold standard.
Spearman’s rank order correlations were run to deter-
mine the relationship between serum tryptase levels
and percentage of MC in the BM. The Mann-Whitney
test was applied to compare serum tryptase levels
between patients with SM and individuals with CM.
RESULTS
Twenty-four adult patients with mastocytosis
were studied, and 14 (58%) of these individuals were
women. The median age of disease onset was 34
years, and ranged from 2 to 75 years, while the medi-
an age at first clinic visit was 45 years, and ranged
from 18 to 75 years. Most patients (75%) were referred
by Dermatology, followed by Hematology (12.5%),
Internal Medicine (8.3%) and other services (4%). The
median time of follow-up was 10 years (range: 1 to 27
years) from the first manifestation of the disease, 9
years (range: 6 months to 26 years) from the diagnosis
of mastocytosis and 42 months (range: 3 to 108
months) from the first visit to the multidisciplinary
clinic for cutaneous lymphomas.
Cutaneous manifestations were observed in 23
(96%) patients (Table 1). Urticaria pigmentosa (UP) was
seen in 21 patients (88%) (Figure 1). One patient pre-
sented with telangiectasia macularis eruptiva perstans
(TMEP), and another had multiple cutaneous anetoder-
ma lesions (Figure 2). Pruritus, which was usually
moderate and typically described as itching of the
lesions, was the most frequent symptom, being present
in 15 patients (63%). Gastrointestinal and neuropsychi-
atric manifestations were seen in 6 (25%) and 5 (21%)
patients, respectively. One patient had severe systemic
MC mediator-related symptoms, consisting of episodes
of flushing, hypotension and syncope (Table 1).
Skin biopsies were performed in all patients
with cutaneous manifestations (96%), and in all cases,
skin involvement was confirmed. Pathological find-
ings included multifocal aggregates of MC in the
upper dermis and perivascular areas (Figure 3).
Whenever necessary, CD117 immunostaining was
used to identify MC in biopsy specimens (skin and
BM). Elevated total serum tryptase levels (range: 2 to
194 µg/L) were found in 14 cases (58%) at the first
clinical assessment. BM examinations were performed
in 19 (79%) patients, all of whom were biopsied.
Aspirate smears were examined for 18 (75%) patients,
and 16 (67%) individuals underwent MC
immunophenotyping by flow cytometry.
FIGURE 1: Urticaria pigmentosa lesions: multiple hyperpigmented
red-brown maculae and papules
FIGURE 2: Anetodermic lesions: multiple small, circumscribed, skin-colo-
red, wrinkled patches that may bulge slightly and herniate into the skin
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In order to evaluate the properties of each WHO
criteria for the diagnosis of SM, their sensitivity, speci-
ficity, negative predictive value (NPV), positive predic-
tive value (PPV) and efficiency were calculated (Table
2). BM biopsy confirmed systemic involvement in 11
(58%) of the 19 patients. Of the eight patients with no
apparent BM abnormalities, 3 had CM and 5 had SM
(false negatives), as later confirmed by other diagnos-
tic methods (Table 2). Of the 18 patients who under-
went BM aspirate examination, 12 (67%) showed sys-
temic involvement. Features of neoplastic MC includ-
ed the presence of cytoplasmic processes, atypical
nuclei and spindled, degranulated and hypogranulat-
ed forms (Figure 4). Atypical MC morphology was not
observed in the remaining six patients. Three of these
patients were true negatives (patients with CM), while
the other three were diagnosed with SM (Table 2).
Twelve (92%) of the 13 SM patients whose BM MC
were analyzed by flow cytometry were found to have
BM involvement, as detected by the presence of phe-
notypically abnormal CD25+ and/or CD2+ MC
(Figure 5). In the remaining case, flow cytometry was
inconclusive (unrepresentative BM aspirate). Flow
cytometry analysis was able to detect an aberrant MC
population as low as 0.004%. In 3 patients, the BM MC
showed a normal phenotype, confirming that masto-
cytosis was limited to the skin (Table 2).
Systemic involvement was confirmed in 16
patients, of whom 15 were diagnosed with ISM and
one with SM-AHNMD (myeloproliferative syndrome,
MPS),  and CM was diagnosed in 3 patients. In 5 cases,
a definitive differential diagnosis between MC and
MS could not be established, since BM involvement
was not evaluated. Eleven (69%) of the 16 SM patients
who met the major criterion (multifocal dense infil-
trates of MCs detected in the BM and/or in other
Condition Manifestation Number (percentage)
Cutaneous manifestations urticaria pigmentosa 21 (88%)
Telangiectasia macularis eruptiva perstans 1 (4.2%)
Anetoderma 1 (4.2%)
Total 23 (96%)
Symptons* Pruritus 15 (63%)
Gastrointestinal 6 (25%)
Neuropsychiatric 5 (21%)
Flushing, hypotensions and syncope 1 (4.2%)
TABLE 1: Description of patients’ cutaneous manifestations and symptoms 
Footnotes: * Each patient could show more than one symptom
FIGURE 3: Histopathological findings in a skin specimen from a patient
with urticaria pigmentosa lesions showing multifocal mast cell aggrega-
tes in the dermis (hematoxylin-eosin staining, 200x magnification)
FIGURE 4: Bone marrow aspirate smear from a patient with systemic
mastocytosis, revealing a morphologically atypical mast cell with fusi-
form shape, polar cytoplasmatic processes, hypogranularity and atypi-
cal nuclei (Leishman’s staining, 400xmagnification)
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extracutaneous organs) also met ≥2 minor criteria. The
remaining 5 (31%) patients were diagnosed with SM
based on the presence of ≥3 minor criteria.
Hematologic abnormalities were present in 38%
of SM patients and included anemia, leucopenia,
leukocytosis and thrombocytopenia. Bone densitome-
try revealed signs of osteoporosis in three patients,
and two patients were found to have
hepatosplenomegaly.
Who Organ Laboratorial Sensitivity Specificity Negative Positive Efficiency
criteria (sample) finding pedictive pedictive
value value
Major Bonemarrow Multifocal dense infiltrates 11/16(69%) 3/3(100%) 3/8(38%) 11/11(100%) 14/19(74%)
(biopsy) (i) of mast cells
Minor Bone marrow Atypical mast cell 12/15(80%) 3/3(100%) 3/6(50%) 12/12(100%) 15/18(83)
(smcar) morphology
Minor Bone marrow Aberrant phenotype 12/13(92%) 3/3(100%) 3/4(75%) 12/12(100%) 15/16(94%)
(aspirate)(ii) (iii) (iv)
Minor Peripheral Elevated serum tryptase 12/16(75%) 3/3(100%) 3/7(43%) 12/12(100%) 15/19(79%)
Blood (iv) (>20µg/L) (vii) (viii) (ix)
TABLE 2: Title: Sensitivity, specificity, predictive values and efficiency of each World Health Organization crite-
rion used in this study for the diagnosis of systemic mastocytosis 
Footnotes: (i) Bone marrow analysis was not performed in 5 patients, one of whom had increased serum tryptase levels; (ii) One of these
cases had an unrepresentative BM aspirate; if this case is not included in the analysis, the following values are obtained: (iii) 12/12 (100%),
(iv) 3/3 (100%) and (v) 15/15 (100%); (vi) One of these cases was SM-AHNMD (MPD); if serum tryptase levels are not used as diagnostic
criteria in this case, the following values are obtained: (vii) 12/15 (80%); (viii) 3/6 (50%) and (ix) 15/18 (83%)
FIGURE 5: Typical dot-
plots showing phenotypi-
cally abnormal CD117+,
CD25+, CD2+ neoplastic
mast cells (pink dots)
identified by flow cyto-
metry in the bone mar-
row aspirate from a
patient with systemic
mastocytosis
Associated diseases were present in five
patients. Two of these individuals had autoimmune
cytopenias (anemia and thrombocytopenia in one
patient; thrombocytopenia in another), one had  BCR-
ABL negative myeloproliferative disorder, another
had anetoderma, while the remaining participant was
diagnosed with colon carcinoma. One patient evolved
from ISM to ASM 13 years after disease onset. Years
before any evidence of disease progression was
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detected, this patient was found to carry the activating
D816V mutation of the  C-KIT gene in both MC and
myeloid non-mast BM cells, while the patient diag-
nosed with systemic MC-mediator related symptoms
was found to carry the activating V560G in BM MCs
only. The other cases were not investigated for the
presence of C-KIT mutations, since molecular analy-
ses are not routinely performed in the hospital.
All patients were treated with antihistamines
with some clinical response. Sodium cromoglycate
(200 mg orally 5 times per day) was used by 22 (92%)
patients with variable clinical benefit. One patient was
treated with alpha-interferon  (3MU, 3 times a week,
subcutaneously) over 8 weeks without clinical
response. The patient who progressed to ASM
received corticosteroids and hydroxyurea for 6
months with limited clinical benefit and refused fur-
ther treatment. A transient response was observed in
patients with associated autoimmune cytopenias, all
of whom were treated with oral corticosteroids and
intravenous high-dose immunoglobulins.
DISCUSSION
Mastocytosis has been found to involve the skin
in approximately 80% of cases. In agreement with
other studies, the present results showed that UP was
the most common skin manifestation of mastocytosis.13
Only one patient was found to have atypical cuta-
neous alterations in the form of secondary anetoder-
ma. Anetodermic lesions are an unusual clinical pres-
entation of mastocytosis.16,17 MCs play an important
role in the development of anetodermic lesions, as they
release different mediators which interfere with colla-
gen synthesis and increase the fragmentation of elastic
fibers. Moreover, the chemotactic substances released
during mastocyte degranulation induce the accumula-
tion of eosinophils, neutrophils and macrophages,
which might promote elastase activity.18
Cases of suspected CM should be investigated
by skin biopsy. In the present study, cutaneous biop-
sies were performed in all patients with skin lesions.
Typically, MC are more abundant in UP lesions than in
normal skin. However, small increases in MC num-
bers have also been reported in patients with other
conditions, such as unexplained flushing, chronic
urticaria, and atopic dermatites.19,20
The diagnostic approach to SM usually starts
with BM analysis, since this site is almost universally
involved in adult mastocytosis, and its examination
allows for the detection of  second hematologic neo-
plasms.8,21,22 In the vast majority of cases (90%), SM can
be diagnosed by BM examination alone (major criteri-
on). However, the fact that multifocal and dense MC
infiltrates (major criterion for SM according to the
WHO classification) were only observed in 69% of our
patients suggested that this criterion has a low NPV
(38%) and low efficiency (74%) for diagnosing SM
(Table 2). This can be explained in part by the intrinsic
subjectivity of this analysis, and also by the fact that,
in some cases, it can be especially difficult to identify
the typical features of mastocytosis in the BM, espe-
cially when MC are significantly hypogranulated or
when significant reticulin fibrosis is present.8 Tryptase
appears to be the most sensitive immunohistochemi-
cal marker of the disease. However, tryptase testing
was not available in the hospital studied, so that in
some cases, CD117 immunostaining was performed to
identify MC in biopsy specimens.
Atypical MC morphology in BM smears was
observed in 80% of patients. This criterion had  high-
er sensitivity, NPV and efficiency in diagnosing SM
than the presence of dense infiltrates of MC in BM
specimens (Table 2).
MC immunophenotyping by flow cytometry
proved to be an excellent method for screening for SM
(sensitivity, NPV and efficiency of 92%, 75% and 94%,
respectively; all values increased to 100% when only
cases with representative BM aspirates were consid-
ered) (Table 2). Currently, CD117 is considered to be
the best immunological marker of mature MC.23 It can
also be found in normal and pathological MC, as well
as in several other cells such as CD34+ hematopoietic
stem and progenitor cells, myeloid precursors,
CD56bright NK cells, and neoplastic cells from patients
with various hematological and non-hematologic
malignancies.24 However, MC usually express much
higher levels of CD117 than other CD45+ hematopoi-
etic cells, and the combined analysis of CD117 expres-
sion and light scatter properties allows for the identi-
fication of MC by flow cytometry (Figure 5).1,23
Neoplastic MC are usually CD2 and/or CD25 posi-
tive, and the abnormal expression of at least one of
these two antigens is considered a minor criterion
according to the 2008 WHO classification. In the pres-
ent study, CD25 positivity appeared to be the most
sensitive and specific method to identify neoplastic
MC, a finding which is in accordance with the litera-
ture23. All CM patients in the present sample had nor-
mal serum tryptase levels, and 13 (81%) of the 16
patients with confirmed SM showed elevated tryptase
levels, leaving a total of three patients with systemic
involvement but normal levels of serum tryptase.
Although the present data confirm previous reports
suggesting that the measurement of serum tryptase
levels is a reliable noninvasive diagnostic approach to
monitor MC burden in patients with mastocytosis,  it
is important to emphasize that this test has limited
diagnostic utility for SM screening due to its relative-
ly low sensitivity, NPV and efficiency (75%, 43% and
79%, respectively; these values increased to 80%, 50%
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and 83% when the patient with SM-AHNMD was
excluded from the analysis) (Table 2).25 Moreover, it is
known that serum tryptase levels can be temporarily
elevated during severe allergic reactions, and in a sig-
nificant proportion of cases of acute myeloid leukemia
(AML), myeloproliferative and myelodysplastic syn-
dromes, which limits the diagnostic utility of this test
in individuals with a second SM-associated myeloid
neoplasm.1,12,26 One study has reported that approxi-
mately 5% of AML patients have serum tryptase lev-
els > 200 µg/L, possibly due to the presence of associ-
ated SM.27 Myeloid disorders account for 80-90% of
cases of SM–AHNMD. For these reasons, the WHO
classification states that this criterion cannot be used
reliably in patients with an associated myeloid disor-
der. Plasma cell myeloma is the most frequent lym-
phoid malignancy associated with SM.28 It is not com-
pletely clear whether elevated serum tryptase levels
are diagnostically effective in cases of SM associated
with lymphoid neoplasms.25 According to the litera-
ture, the proportion of ASM and SM-AHNMD
patients who exhibit markedly elevated serum
tryptase levels (> 200 µg/L) is significantly higher
than that proportion among ISM patients.4,8 In the
present study, the patient with SM-AHNMD (MPD)
had normal serum tryptase levels.
Despite their variable sensitivity and  NPV, all
WHO criteria proved to have high specificity and PPV for
diagnosing of SM (100% in our series) (Table 2). Despite
the sample limitations, the present results suggested that
patients who met these criteria had a significantly higher
probability of systemic disease.
Of the 16 patients diagnosed with SM, 11 (69%)
met both the major criterion and ≥2 minor criteria. The
remaining 5 (31%) patients were diagnosed based
only on the presence of ≥3 minor criteria. These find-
ings are similar to other reports. A study of 53 patients
with SM reported the presence of the major criterion
in 68% of the sample.25 Atypical MC morphology was
observed in 100% of patients, an aberrant
immunophenotype was identified in 96% of individu-
als, and elevated serum tryptase (>20 µg/L) levels
were detected in 85% of the sample.25 Spearman’s rank
order correlation was used to determine the relation-
ship between serum tryptase levels and the percent-
age of MC in the BM. A positive correlation was found
between the two variables (r  = 0.340, P< 0.05). The
Mann-Whitney test was applied to compare serum
tryptase levels between patients with SM and those
with CM, and it was found that patients with CM had
significantly lower levels of serum tryptase than SM
patients (P=0.014).
The conclusions of the present study regarding
genetic aberrations are limited by the fact that the
molecular analysis of MC is not routinely performed in
our hospital, and only two cases were evaluated using
this procedure. The patient who presented the D816V
mutation, which is common in patients with adult
onset SM, showed disease progression from indolent
to aggressive SM 13 years after the first disease mani-
festation.29 This is in accordance with the fact that indi-
viduals who carry this mutation in BM MC, CD34+
hematopoietic precursors and mature non-mast
myeloid cells tend to have a poorer prognosis.13 In con-
trast, the patient whose BM MC displayed the Val-
560(r)Gly mutation, which is rare in both children and
adult patients with mastocytosis, had an atypical pres-
entation of SM, displayed associated CM and showed
no evidence for disease progression for 19 years after
the initial diagnosis.13 It is unclear whether these muta-
tions play a causal or permissive role, where addition-
al factors are necessary to develop ISM and/or ASM,
and whether they may influence the response to differ-
ent tyrosine kinase inhibitors, as suggested by  in
vitro studies with mast cell leukemia cell lines.30
CONCLUSION
When considered individually, the WHO crite-
ria have different degrees of diagnostic utility for SM.
Although all criteria have high specificity and PPV for
the diagnosis, their sensitivity, NPV and efficiency is
highly variable. The present results suggested that
flow cytometry based immunophenotypic analysis of
BM MC was the most adequate test for SM screening
due to its high sensitivity and NPV. Serum tryptase
analysis also has relatively good sensitivity for diag-
nosing SM, and may provide an indirect measure of
MC mass. However, normal serum tryptase levels can-
not be used to exclude systemic involvement due to
their low NPV. Thus, when serum tryptase levels are
found to be normal, the BM should be evaluated and
MC phenotypes should be analyzed by flow cytome-
try. Other conventional methods, such as BM smears
and biopsy, in that order, could also be used for a cor-
rect evaluation of systemic disease. Further studies are
necessary to explain the differences between ISM and
ASM, disease progression and the association between
SM and other hematologic disorders in some patients.
To help with this process, new algorithms are being
proposed for a better diagnostic definition and prog-
nostic classification of these disorders.31 q
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